CD274 and neoplasm: PD-1/PD-L1 inhibitor monotherapy has demonstrated efficacy in various solid tumour types, including mismatch repair-deficient/microsatellite instability-high tumours, high tumour mutation burden tumours and some PD-L1-high tumours [3–5].